Date: 2011-12-08
Type of information:
phase: 2
Announcement: completion of patient recruitment
Company: Synairgen (UK)
Product: inhaled interferon beta (IFN-beta)
Action mechanism:
Disease: exacerbation-prone asthmatics
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country:
Trial details:
Latest
news: Synairgen, the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, has announced that the last subject has been successfully recruited into its Phase II proof of concept clinical trial of inhaled IFN-beta in exacerbation-prone asthmatics. The Company is on schedule to announce the results of the study in late Q1 2012.
